Cargando…

Vaccines against SARS‐CoV‐2 are safe to administer in patients with antibodies to pegaspargase

OBJECTIVE: Allergic reactions to pegaspargase during ALL therapy are typically due to antibodies against polyethylene glycol (PEG), which is also used as a stabilizing agent in mRNA‐based SARS‐CoV‐2 vaccines. To evaluate the safety of these vaccines in patients with anti‐pegaspargase antibodies. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swanson, Hope D., Hakim, Hana, Hijano, Diego R., Morton, Ted, Cross, Shane, Inaba, Hiroto, Jeha, Sima, Pui, Ching‐Hon, Karol, Seth E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	BRIEF COMMUNICATION
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349948/ https://www.ncbi.nlm.nih.gov/pubmed/35837830 http://dx.doi.org/10.1002/cam4.5011

Ejemplares similares

1155. Covering Your Tracts? The Effect of Antibiotic Prophylaxis on Respiratory Tract Infections in Pediatric Acute Lymphoblastic Leukemia
por: Strength, Rachel, et al.
Publicado: (2021)

Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase
por: Faschinger, Alexander M., et al.
Publicado: (2019)

Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia
por: Karol, Seth E., et al.
Publicado: (2020)

Pegaspargase Induced Hypertriglyceridemia Resulting in Severe Fatal Pancreatitis
por: Vyas, Neil, et al.
Publicado: (2015)

Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia
por: Inaba, Hiroto, et al.
Publicado: (2021)

Clofarabine treatment of KMT2Ar infantile patients with acute lymphoblastic leukemia in St. Jude Total Therapy Study 16
por: Gruber, Tanja A., et al.
Publicado: (2022)

Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
por: Heo, Young-A., et al.
Publicado: (2019)

Treatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase
por: Yu-tong, Zhang, et al.
Publicado: (2014)

Correction to: Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
por: Heo, Young-A., et al.
Publicado: (2019)

Levocarnitine for pegaspargase‐induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia
por: Schulte, Rachael, et al.
Publicado: (2021)

SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study
por: Hijano, Diego R., et al.
Publicado: (2023)

Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia
por: Karol, Seth E., et al.
Publicado: (2020)

Perforated jejunitis in a child with acute lymphoblastic leukemia treated with pegaspargase
por: Tang, Elizabeth R., et al.
Publicado: (2018)

Healthcare-Associated Infections Caused by Mycolicibacterium neoaurum
por: Shapiro, Kate, et al.
Publicado: (2023)

S107: IDENTIFICATION AND CHARACTERIZATION OF GERMLINE NBN VARIANTS RELATED TO B-ALL PREDISPOSITION
por: Escherich, Carolin, et al.
Publicado: (2023)

Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia
por: Karol, Seth E., et al.
Publicado: (2023)

mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase
por: Koo, Grace, et al.
Publicado: (2022)

Antibiotic prophylaxis and the gastrointestinal resistome in paediatric patients with acute lymphoblastic leukaemia: a cohort study with metagenomic sequencing analysis
por: Margolis, Elisa B, et al.
Publicado: (2021)

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma
por: Fu, Ruiying, et al.
Publicado: (2023)

Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia
por: Ramsey, Laura B., et al.
Publicado: (2015)

Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy
por: Karol, Seth E., et al.
Publicado: (2021)

Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response
por: Lee, Shawn H. R., et al.
Publicado: (2023)

Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children
por: Escherich, Carolin, et al.
Publicado: (2023)

Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review
por: Bender, Cynthia, et al.
Publicado: (2021)

Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to the age of 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Geyer, Mark B., et al.
Publicado: (2020)

Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia
por: Nookala Krishnamurthy, Manjunath, et al.
Publicado: (2020)

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
por: Sun, Peng, et al.
Publicado: (2022)

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
por: Bassan, Renato, et al.
Publicado: (2023)

A nucleic acid amplification test‐based strategy does not help inform return to work for healthcare workers with COVID‐19
por: Hijano, Diego R., et al.
Publicado: (2022)

The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
por: Zhang, Lei, et al.
Publicado: (2016)

P386: COMPARISON OF THE PHARMACOKINETICS OF THE LIQUID AND THE LYOPHILIZED FORMULATIONS OF PEGASPARGASE IN THE TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
por: Karachunskiy, Alexander, et al.
Publicado: (2023)

Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report
por: Li, Dan, et al.
Publicado: (2023)

Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy
por: Pui, Ching-Hon, et al.
Publicado: (2016)

Successful treatment with rivaroxaban of cerebral venous thrombosis and bone marrow necrosis induced by pegaspargase: A case report and literature review
por: Sui, Jingrui, et al.
Publicado: (2017)

The safety of SARS-CoV-2 vaccines in persons with a known history of pegaspargase allergy: A single institution experience
por: Rush, Cassandra, et al.
Publicado: (2022)

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
por: Yan, Zheng, et al.
Publicado: (2020)

Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study
por: Zhong, Huijuan, et al.
Publicado: (2023)

Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol
por: Duffy, Caitlyn, et al.
Publicado: (2022)

Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies
por: Robinson, Katherine M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hbojfut1lpvt2jj1ujaraeu0e3